Even though all immunoglobulin intravenous (IGIV) end products have high IgG concentrations, variations in manufacturing processes lead to unique product characteristics. Solvent/detergent-treated IGIV (IGIV-S/D) liquid 10% (Gammagard or Kiovig liquid) is one of the newer products, and this article will discuss and compare its efficacy, safety, tolerability and effect on patient care. The search terms 'immunoglobulin,' 'IGIV,' 'IVIG,' and 'liquid' were entered into PubMed/Medline and Google for the literature search in preparation of this manuscript. Additional references were screened from researched literature. Gammagard liquid 10% has shown significant activity in primary immunodeficiency and immune thrombocytopenic purpura. It is a sugar- and sodium-free product with improved safety, tolerability and convenience. Overall, Gammagard liquid is a valuable addition to available therapies that has utility in life-threatening and complicated diseases, and its use will continue to grow.